Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey
V Bertaglia, S Vallone, MV Pacchiana… - Lung Cancer …, 2017 - Taylor & Francis
Lung cancer is the leading cause of cancer-related deaths in worldwide, and NSCLC
represents around 85% of all lung cancers. Squamous cell lung cancer (SqCLC) is the …
represents around 85% of all lung cancers. Squamous cell lung cancer (SqCLC) is the …
[PDF][PDF] 晚期非小細胞肺癌之化學治療與標靶治療
柯獻欽， 鄭高珍 - 內科學誌, 2018 - tsim.org.tw
摘要肺癌是常見且死亡率很高的癌症, 根據衛生福利部死因統計: 2016 年台灣有9,372
人死於肺癌, 佔所有死亡人數的5.4%, 無論是男性或女性, 肺癌都佔癌症死亡原因的第一位 …
人死於肺癌, 佔所有死亡人數的5.4%, 無論是男性或女性, 肺癌都佔癌症死亡原因的第一位 …
[HTML][HTML] Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of …
A Lisberg, EB Garon - Translational lung cancer research, 2017 - ncbi.nlm.nih.gov
In the TAILOR (Tarceva Italian Lung Optimization Trail), erlotinib was compared to docetaxel
in EGFR-wt patients as second line therapy and the ORR in EGFR-wt patients to erlotinib …
in EGFR-wt patients as second line therapy and the ORR in EGFR-wt patients to erlotinib …
Placebo effect in the treatment of non-small cell lung cancer: a meta-analysis
S Ren, M Ma, C He, Y Deng, X Chen, Y Liu… - Journal of Bio-X …, 2022 - spj.science.org
Objective: The majority of non-small cell lung cancer (NSCLC) cases remain undiagnosed
until advanced stages of the disease. Accumulating studies have highlighted the utility of …
until advanced stages of the disease. Accumulating studies have highlighted the utility of …
[PDF][PDF] 肺癌气道播散的研究概况
吴越， 武韫， 牛玉旭， 范力文… - Progress in Modern …, 2019 - biomed.cnjournals.com
2015 年, 世界卫生组织对肺癌的分类提出了气道播散(spread through air spaces, STAS)
的概念, 作为肺腺癌侵袭的新模式. STAS 指的是肺癌细胞在肺实质内经气道播散到肿瘤主灶 …
的概念, 作为肺腺癌侵袭的新模式. STAS 指的是肺癌细胞在肺实质内经气道播散到肿瘤主灶 …
[图书][B] The Epidermal Growth Factor Receptor: A target for the treatment of non-small cell lung cancer
O Smith - 2020 - search.proquest.com
Upregulation and mutation of EGFR has been linked to many diseases, particularly non-
small cell lung cancer (NSCLC), which accounts for approximately 80% of lung cancer …
small cell lung cancer (NSCLC), which accounts for approximately 80% of lung cancer …
[HTML][HTML] Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non …
Background: We planned to compare pemetrexed maintenance with erlotinib maintenance
in non squamous non Epidermal Growth Factor Receptor (EGFR) mutated non small cell …
in non squamous non Epidermal Growth Factor Receptor (EGFR) mutated non small cell …
Targeted Therapies in Cancer Treatment
IDL Cavalcanti, JCS Soares, IDL Cavalcanti… - Advances in Cancer …, 2021 - Springer
In this chapter, we discuss what are the major receptors overexpressed in tumor cells and
how these receptors have been widely tested as a targeted therapy in the treatment of …
how these receptors have been widely tested as a targeted therapy in the treatment of …
New options on the horizon for nononcogene addicted non-small-cell lung cancer
L Paglialunga, S Ricciardi, M D'Arcangelo - Future Oncology, 2018 - Taylor & Francis
The treatment of non-small-cell lung cancer (NSCLC) has historically been based on
platinum doublets-and taxan-based chemotherapy in the first-and second-line therapy …
platinum doublets-and taxan-based chemotherapy in the first-and second-line therapy …
[HTML][HTML] Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells
A Li, W Cao, X Liu, Y Zhang, Y Ma, R Xu… - Translational Cancer …, 2020 - ncbi.nlm.nih.gov
Background Gefitinib is a first-generation epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) that has become first-line treatment for patients with mutant EGFR non …
inhibitor (EGFR-TKI) that has become first-line treatment for patients with mutant EGFR non …